S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease

Circulation Journal

Volumn 76, Issue 11, 2012, Pages 2647-2652

  Saito, Toshinobu ^a   Hojo, Yukihiro ^a   Ogoyama, Yukako ^a   Hirose, Masahiro ^a   Ikemoto, Tomokazu ^a   Katsuki, Takaaki ^a   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Inflammation; Leukocyte

Indexed keywords

AMIODARONE; C REACTIVE PROTEIN; PROTEIN S 100; S100A12 PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHERECTOMY; BARE METAL STENT; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTED HEART PACEMAKER; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SURVIVAL RATE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DEATH; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; S100 PROTEINS;

EID: 84869139717     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0093     Document Type: Article

References (31)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Holmes DRJ, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640.
3. Weisz G, Leon MB, Holmes DRJ, Kereiakes DJ, Clark MR, Cohen BM, et al. Two-year outcomes after sirolimus-eluting stent implantation: Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006; 47: 1350-1355.
4. Weisz G, Leon M, Holmes DRJ, Kereiakes D, Popma J, Teirstein P, et al. Five-year follow-up after sirolimus-eluting stent implantation: Results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial. J Am Coll Cardiol 2009; 53: 1488-1497.
5. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
6. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
7. Rosario D. S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33: 637-668.
8. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: From evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-1122.
9. Vogl T, Pröpper C, Hartmann M, Strey A, Strupat K, van den Bos C, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999; 274: 25291-25296.
10. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
11. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847-853.
12. Foell D, Seeliger S, Vogl T, Koch HG, Maschek H, Harms E, et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613-617.
13. Niini T, Vettenranta K, Hollmén J, Larramendy ML, Aalto Y, Wikman H, et al. Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia: A cDNA array study. Leukemia 2002; 16: 2213-2221.
14. Ye F, Foell D, Hirono KI, Vogl T, Rui C, Yu X, et al. Neutrophilderived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 2004; 94: 840-844.
15. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, et al. RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135.
16. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-1389.
17. Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270-1272.
18. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
19. Teramoto T. Japan Atherosclerosis Society guidelines for prevention of atherosclerotic diseases in Japanese. Nihon Ronen Igakkai Zasshi 2008; 45: 597-600.
20. Kosaka K. Diagnosis of diabetes mellitus. Nihon Naika Gakkai Zasshi 1982; 71: 759-763.
21. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-753.
22. Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB. Multiple structural states of S100A12: A key to its functional diversity. Microsc Res Tech 2003; 60: 581-592.
23. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: A novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
24. Park H, Baek J, Shin W, Kim D, Jang S, Shin D, et al. Soluble receptor of advanced glycated endproducts is associated with plaque vulnerability in patients with acute myocardial infarction. Circ J 2011; 75: 685-690.
25. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J 2008; 155: 49-55.
26. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999; 100: 96-102.
27. Zebrack JS, Muhlestein JB, Horne BD, Anderson JL; Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: Independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39: 632-637.
28. Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T, et al. Risk stratification of chronic heart failure patients by multiple biomarkers: Implications of BNP, H-FABP, and PTX3. Circ J 2008; 72: 1800-1805.
29. Ferratini M, Ripamonti V, Masson S, Grati P, Racca V, Cuccovillo I, et al. Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients. J Cardiopulm Rehabil Prev 2012; 32: 17-24.
30. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011; 57: 861-869.
31. Sinning C, Sinning J, Schulz A, Schnabel R, Lubos E, Wild P, et al. Association of serum procalcitonin with cardiovascular prognosis in coronary artery disease. Circ J 2011; 75: 1184-1191.